In contrast, co-occurring STK11/KEAP1 mutations, probably due to the STK11 impact on “cold” tumour microenvironment, lead to lower levels of PD-L1 expression and decreased response to immunotherapy. The gene discussed is STK11; the disease is neoplasm.